Clinical trials: Malignant Melanomas
Melanoma
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
Recent studies suggest that patients with metastatic melanoma whose gut microbiome is colonized by eubiotic bacteria have a stronger anti-cancer response to anti CTLA-4 and anti PD1.
- Trial name
- PICASSO (NCT04988841)
- Testing
- MaaT013, Ipilimumab, Nivolumab
- Where
- 5 sites in France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HLA-A2 Positive Cells Present, Refractory Melanoma
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to…
- Trial name
- NCT04093323
- Testing
- Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Choroidal Melanoma
Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma
This is a report of 10 years results of combined Transpupillary thermotherapy (TTT) treatment with Indocyanine green (ICG) in controlling small and medium-sized choroidal melanomas.
- Trial name
- NCT01253759
- Testing
- TTT + ICG-based PDT
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- New England Retina Associates
Malignant Melanoma
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant melanoma.
- Trial name
- NCT00142454
- Testing
- Imiquimod, NY-ESO-1 protein
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Melanoma
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
The purpose of this study is to learn about the effects of 3 study medicines (encorafenib, binimetinib, pembrolizumab) compared to 2 study medicines (ipilimumab and nivolumab) given for the treatment of melanoma.
- Trial name
- PORTSIDE (NCT05926960)
- Testing
- encorafenib, binimetinib, pembrolizumab
- Where
- 24 sites in Germany, Italy and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Melanoma, Genetic Polymorphism
Multicentric Cohort of Melanoma Patients in Ile de France Area
This is a multicentric prospective cohort of all stage melanoma patients from AP-HP ,the largest consortium of University hospitals over Europe.
- Trial name
- Melan-Cohort (NCT00839410)
- Where
- France
- Volunteers
- 1,255 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Malignant Melanoma
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with vemurafenib or vemurafenib plus cobimetinib in…
- Trial name
- NCT01656642
- Testing
- Atezolizumab, Cobimetinib, Vemurafenib
- Where
- 8 sites in United States
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Cutaneous Melanoma, Melanoma Stage IV
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
Clear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition Bristol-Myers Squibb (BMS986213) is superior to…
- Conditions
- Cutaneous Melanoma, Melanoma Stage IV, Mucosal Melanoma
- Trial name
- ClearMe (NCT06319196)
- Testing
- Opdualag, Nivolumab
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- University Health Network, Toronto
Metastatic Melanoma, Skin Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving…
- Trial name
- NCT01468818
- Testing
- Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin
Intratumoral PH-762 for Cutaneous Carcinoma
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the…
- Conditions
- Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
- Trial name
- NCT06014086
- Testing
- PH-762
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Phio Pharmaceuticals Inc.
Metastatic Melanoma
Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma
The aim of this research project is to determine whether a short bout of physical exercise immediately before the start of immunotherapy (Nivolumab and Ipilimumab) is feasible and has a positive effect on the effectiveness of…
- Trial name
- SPRINT (NCT07564570)
- Testing
- 30 Minutes Cycle Ergometer
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Stage IIA Skin Melanoma, Stage IIB Skin Melanoma
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
This randomized pilot clinical trial studies melanoma antigen recognized by T-cells 1 (MART-1) antigen with or without toll-like receptor 4 (TLR4) agonist glucopyranosyl lipid A-stable oil-in-water emulsion (GLA-SE) in treating…
- Conditions
- Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT02320305
- Testing
- MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Melanoma
Phase I trial to study the effectiveness of vaccine therapy in treating patients with melanoma that cannot be treated with surgery. Vaccines may make the body build an immune response that may kill tumor cells.
- Trial name
- NCT00003556
- Testing
- ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Breast Cancer
Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy
Success of cancer immunotherapy is limited by the ability of solid tumors to evade local and systemic antitumoral immune responses.
- Conditions
- Prostate Cancer, Breast Cancer, Lung Cancer, Melanoma
- Trial name
- SBRT (NCT01777802)
- Testing
- SBRT, IMRT, Brachytherapy
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma.
- Trial name
- NCT04674683
- Testing
- HBI-8000 in combination with nivolumab
- Where
- 139 sites in United States, Australia and 15 more
- Volunteers
- 450 people
- Sponsor
- HUYABIO International, LLC.
Melanoma
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
This study will examine the effectiveness of treating advanced melanoma with special tumor-fighting cells taken from the patient's blood or tumor and grown in the laboratory.
- Trial name
- NCT00080353
- Testing
- IL-2, gp100:209-217, OKT3
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma that has not responded to…
- Trial name
- NCT00019994
- Testing
- MART-1 antigen, aldesleukin, gp100 antigen
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma, TOR Serine-Threonine Kinases
Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study
This is a single-armed, open-labeled and single-centered study of everolimus in selective patients with metastatic melanoma for evaluation of the efficacy and safety.
- Conditions
- Melanoma, TOR Serine-Threonine Kinases, Neoplasm Metastasis
- Trial name
- NCT01960829
- Testing
- Everolimus
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma
Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma
Rationale: Ipilimumab, a monoclonal antibody targeting CTLA-4, is approved for the treatment of metastatic melanoma and significantly increases median overall survival.
- Trial name
- Zirconipi (NCT03313323)
- Testing
- 89Zirconium-labeled ipilimumab
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- Amsterdam UMC, location VUmc
Melanoma (Skin)
Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00085462
- Testing
- aldesleukin, filgrastim, gp100-fowlpox vaccine
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.